High Dose Radiotherapy for Palliation (Hi-D)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBritish Columbia Cancer Agency
About this trial
Palliative radiation is effective for controlling or preventing symptoms such as pain, bleeding, dyspnea, and cord compression. Recently, studies have shown that additional dose escalation may result in superior local control. The investigators propose a phase II single arm trial to evaluate a novel high-dose radiation regimen, which will be 27 Gray in 3 fractions with dose escalation within the tumour (Hi-D).
Eligibility criteria
Qualifiers
Age 18 or older.
Able to provide informed consent
Patient has histologically confirmed solid tumour malignancy
ECOG performance status 0 - 2
Disqualifiers
Hematologic malignancy
Disease limited to intracranial sites
Serious medical co-morbidities precluding radiotherapy
Prior radiation to target lesion that precludes delivery of repeat radiation. All such cases should be discussed with the local and study PIs.
Trial design
Treatments tested in this trial
- Palliative Radiotherapy
- Palliative Radiotherapy
Treatment groups
21 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov